COVID-19肺炎非重症患者深静脉血栓研究
这项前瞻性队列研究纳入57例住院COVID-19肺炎非重症患者,采用压迫双功能超声筛查深静脉血栓。院内深静脉血栓发生率为10.5%,所有血栓患者均在接受低分子肝素预防。预防性抗凝者血栓风险高于中强度或完全抗凝者,后者显示保护作用。
要点
- 非重症COVID-19肺炎患者院内深静脉血栓发生率为10.5%。
- 规范低分子肝素预防下仍出现深静脉血栓。
- 中强度或完全抗凝可能与更低深静脉血栓风险相关。
核心结论
- 非重症住院COVID-19肺炎患者在接受规范血栓预防情况下仍有较高深静脉血栓风险。
研究设计与样本
- 前瞻性队列研究,初始纳入67例住院COVID-19肺炎患者,经纳入排除标准后57例进入分析。
- 采用鼻咽拭子聚合酶链反应确诊COVID-19,采用B模式压迫双功能超声检查深静脉。
主要发现
- 57例患者中6例诊断深静脉血栓,院内深静脉血栓发生率为10.5%。
- 所有发生深静脉血栓的患者均在接受低分子肝素预防。
临床怎么用
- 对非重症住院COVID-19肺炎患者应警惕深静脉血栓,即使已用低分子肝素预防。
- 可考虑用压迫双功能超声筛查深静脉血栓。
- 抗凝强度选择需权衡血栓与出血风险,中强度或完全抗凝的获益需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Venous thromboembolic events have been one of the main causes of mortality among hospitalized patients with coronavirus disease 2019 (COVID-19) pneumonia. The aim of our study was to describe the prevalence of deep vein thrombosis (DVT) in noncritically ill patients with COVID-19 pneumonia and correlate such observations with the thromboprophylaxis received. METHODS: We performed a prospective cohort study of 67 patients admitted to the hospital for COVID-19 pneumonia. The diagnosis was confirmed using polymerase chain reaction testing of nasopharyngeal specimens. The deep veins were examined using compression duplex ultrasonography with the transducer on B-mode. The patients were separated into two groups for statistical analysis: those receiving low-molecular-weight heparin prophylaxis and those receiving intermediate or complete anticoagulation treatment. Risk analysis and logistic regression were performed. RESULTS: Of the 67 patients, 57 were included in the present study after applying the inclusion and exclusion criteria; 49.1% were women, and the patient mean age was 71.3 years. All 57 patients had undergone compression duplex ultrasonography. Of these 57 patients, 6 were diagnosed with DVT, for an in-hospital rate of DVT in patients with COVID-19 pneumonia of 10.5%. All the patients who had presented with DVT had been receiving low-molecular-weight heparin prophylaxis. The patients receiving prophylactic anticoagulation treatment had a greater risk of DVT (16.21%; 95% confidence interval, 0.04-0.28; P = .056) compared with those receiving intermediate or complete anticoagulation treatment. We also found a protective factor for DVT in the intermediate or complete anticoagulation treatment group (odds ratio, 0.19; 95% confidence interval, 0.08-0.46; P < .05). CONCLUSIONS: Noncritically ill, hospitalized patients with COVID-19 pneumonia have a high risk of DVT despite receipt of correct, standard thromboprophylaxis.
引用
- Jimenez-Guiu X, Huici-Sánchez M, Rmera-Villegas A, et al. Deep vein thrombosis in noncritically ill patients with coronavirus disease 2019 pneumonia: deep vein thrombosis in nonintensive care unit patients. J Vasc Surg Venous Lymphat Disord. 2020. PMID: 32911110. doi:10.1016/j.jvsv.2020.08.028
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。